| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8945200 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
Overall, the addition of selenium to carboplatin/paclitaxel chemotherapy is safe and well tolerated, and does not alter carboplatin pharmacokinetics. A 5000â¯Î¼g dose of elemental selenium as selenious acid is suggested as the dose to be evaluated in a phase II trial.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Mihae Song, Muthu N. Kumaran, Murugesan Gounder, Darlene G. Gibbon, Wilberto Nieves-Neira, Ami Vaidya, Mira Hellmann, Michael P. Kane, Brian Buckley, Weichung Shih, Paula B. Caffrey, Gerald D. Frenkel, Lorna Rodriguez-Rodriguez,